Contract research organization Quintiles made its return to the market last week with a nearly $950 million IPO. The largest CRO was acquired by a private equity syndicate that included Bain Capital back in 2008.
The private equity firms made a strong return on their purchase, but should investors jump in post IPO? In this video, health-care analyst David Williamson weighs the increasing importance of CROs like Quintiles with some of the less attractive aspects of the business.
David Williamson and The Motley Fool have no position in any stocks mentioned. Follow David on Twitter @MotleyDavid. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.